Article (Scientific journals)
Metformin and COVID-19: From cellular mechanisms to reduced mortality.
Scheen, André
2020In Diabetes & metabolism
Peer reviewed
 

Files


Full Text
2020 D&M Metformin and COVID.pdf
Publisher postprint (455.45 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Inflammation; Meta-analysis; Metformin; Mortality; SARS-CoV-2; Type 2 diabetes
Abstract :
[en] Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the role of glucose control has been emphasized to improve the prognosis, the impact of different glucose-lowering agents remains largely unknown. Metformin remains the first-line pharmacological choice for the management of hyperglycaemia in T2DM. Because metformin exerts various effects beyond its glucose-lowering action, among which are anti-inflammatory effects, it may be speculated that this biguanide might positively influence the prognosis of patients with T2DM hospitalized for COVID-19. The present concise review summarizes the available data from observational retrospective studies that have shown a reduction in mortality in metformin users compared with non-users, and briefly discusses the potential underlying mechanisms that might perhaps explain this favourable impact. However, given the potential confounders inherently found in observational studies, caution is required before drawing any firm conclusions in the absence of randomized controlled trials.
Disciplines :
Pharmacy, pharmacology & toxicology
Immunology & infectious disease
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
English
Title :
Metformin and COVID-19: From cellular mechanisms to reduced mortality.
Publication date :
2020
Journal title :
Diabetes & metabolism
ISSN :
1262-3636
eISSN :
1878-1780
Peer reviewed :
Peer reviewed
Commentary :
Copyright © 2020. Published by Elsevier Masson SAS.
Available on ORBi :
since 14 August 2020

Statistics


Number of views
101 (2 by ULiège)
Number of downloads
3 (3 by ULiège)

Scopus citations®
 
120
Scopus citations®
without self-citations
115
OpenCitations
 
97

Bibliography


Similar publications



Contact ORBi